245 related articles for article (PubMed ID: 32698144)
41. Thyrotropin serum concentrations in patients with papillary thyroid microcancers.
Gerschpacher M; Göbl C; Anderwald C; Gessl A; Krebs M
Thyroid; 2010 Apr; 20(4):389-92. PubMed ID: 20210672
[TBL] [Abstract][Full Text] [Related]
42. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
43. [Association between the serum TSH concentration and thyroid cancer incidence].
Li JZ; Jin YJ; Liu X; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):921-4. PubMed ID: 22340102
[TBL] [Abstract][Full Text] [Related]
44. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Berti P; Grasso L; Elisei R; Pinchera A; Vitti P
Endocr Relat Cancer; 2009 Dec; 16(4):1251-60. PubMed ID: 19528244
[TBL] [Abstract][Full Text] [Related]
45. [Relationship between serum thyroxin-stimulating hormone and papillary thyroid micrcarcinoma in nodular thyroid disease].
Jiao J; Zhou Y
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(12):908-11. PubMed ID: 26081052
[TBL] [Abstract][Full Text] [Related]
46. High Serum Thyrotropin Concentrations within the Reference Range: A Predictor of Malignancy in Nodular Thyroid Disease.
Duccini K; de Souza MVL; Delfim R; Aguiar AP; Teixeira P; Vaisman M
Med Princ Pract; 2018; 27(3):272-277. PubMed ID: 29514150
[TBL] [Abstract][Full Text] [Related]
47. Mendelian randomization study of inflammatory bowel disease and bone mineral density.
Wu F; Huang Y; Hu J; Shao Z
BMC Med; 2020 Nov; 18(1):312. PubMed ID: 33167994
[TBL] [Abstract][Full Text] [Related]
48. Exploring the causal pathway from bilirubin to CVD and diabetes in the UK biobank cohort study: Observational findings and Mendelian randomization studies.
Hou L; Li H; Si S; Yu Y; Sun X; Liu X; Yan R; Yu Y; Wang C; Yang F; Wang Q; Xue F
Atherosclerosis; 2021 Mar; 320():112-121. PubMed ID: 33485635
[TBL] [Abstract][Full Text] [Related]
49. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Tuttle RM; Fleisher M; Francis GL; Robbins RJ
J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
[TBL] [Abstract][Full Text] [Related]
50. Effects of Metformin on TSH Levels and Benign Nodular Goiter Volume in Patients Without Insulin Resistance or Iodine Insufficiency.
Dos Santos PB; Gertrudes LN; Conceição FL; de Andrade BM; de Carvalho DP; Vaisman M; Teixeira PFDS
Front Endocrinol (Lausanne); 2019; 10():465. PubMed ID: 31379740
[No Abstract] [Full Text] [Related]
51. Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease.
Pitoia F; Ilera V; Zanchetta MB; Foffano A; Niepomniszcze H
Endocr Pract; 2008 Nov; 14(8):961-6. PubMed ID: 19095593
[TBL] [Abstract][Full Text] [Related]
52. Thyrotropin values in patients with micropapillary thyroid cancer versus benign nodular disease.
Negro R; Valcavi R; Riganti F; Toulis KA; Colosimo E; Bongiovanni M; Grassi P; Giovanella L; Gardini G; Piana S
Endocr Pract; 2013; 19(4):651-5. PubMed ID: 23512387
[TBL] [Abstract][Full Text] [Related]
53. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules.
Kim ES; Lim DJ; Baek KH; Lee JM; Kim MK; Kwon HS; Song KH; Kang MI; Cha BY; Lee KW; Son HY
Thyroid; 2010 Aug; 20(8):885-91. PubMed ID: 20465529
[TBL] [Abstract][Full Text] [Related]
54. [Correlation between serum thyroglobulin and thyroid stimulating hormone in populations with non-toxic goiter].
Hu FN; Jin Y; Teng WP; Yang F; Teng XC; Gao TS; Wang WB; Shi XG; Tao CM
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):936-9. PubMed ID: 12899791
[TBL] [Abstract][Full Text] [Related]
55. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study.
Thayakaran R; Adderley NJ; Sainsbury C; Torlinska B; Boelaert K; Šumilo D; Price M; Thomas GN; Toulis KA; Nirantharakumar K
BMJ; 2019 Sep; 366():l4892. PubMed ID: 31481394
[TBL] [Abstract][Full Text] [Related]
56. Association of Preoperative Serum Thyroid-stimulating Hormone Levels with Thyroid Cancer in Patients with Nodular Thyroid Disease.
Khan MA; Malik N; Khan KH; Shahzad MF
World J Nucl Med; 2017; 16(3):202-205. PubMed ID: 28670178
[TBL] [Abstract][Full Text] [Related]
57. Relationship between vascular endothelial growth factor expression and thyroid stimulating hormone level in benign and malignant thyroid lesions.
Bariya D; Mishra SP; Akshay BR; Kumari S; Akanksha ; Khanna R; Meena RN
J Family Med Prim Care; 2022 Jun; 11(6):2565-2572. PubMed ID: 36119205
[TBL] [Abstract][Full Text] [Related]
58. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH.
Persani L; Preziati D; Matthews CH; Sartorio A; Chatterjee VK; Beck-Peccoz P
Clin Endocrinol (Oxf); 1997 Aug; 47(2):207-14. PubMed ID: 9302396
[TBL] [Abstract][Full Text] [Related]
59. Higher TSH level is a risk factor for differentiated thyroid cancer.
Kim HK; Yoon JH; Kim SJ; Cho JS; Kweon SS; Kang HC
Clin Endocrinol (Oxf); 2013 Mar; 78(3):472-7. PubMed ID: 22924613
[TBL] [Abstract][Full Text] [Related]
60. Effects of controlled ovarian stimulation on thyroid stimulating hormone in infertile women.
Du YJ; Xin X; Cui N; Jiang L; Yang AM; Hao GM; Gao BL
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():207-212. PubMed ID: 30731333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
